Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You and Your Team.

Learn More →

Toward a More Detailed Reporting of MI Reduction in Clinical Trials—A Welcome and Needed Step in the Right Direction

Toward a More Detailed Reporting of MI Reduction in Clinical Trials—A Welcome and Needed Step in... Effect of Evolocumab on Type and Size of Subsequent Myocardial Infarction Original Investigation Research 6. Thygesen K, Alpert JS, Jaffe AS, et al; Writing 9. Sabatine MS, Giugliano RP, Keech A, et al. syndromes: the MIRACL study: a randomized Group on the Joint ESC/ACCF/AHA/WHF Task Force Rationale and design of the Further cardiovascular controlled trial. JAMA. 2001;285(13):1711-1718. doi: for the Universal Definition of Myocardial OUtcomes Research with PCSK9 Inhibition in 10.1001/jama.285.13.1711 Infarction; ESC Committee for Practice Guidelines subjects with Elevated Risk trial. Am Heart J. 2016; 12. Arora S, Strassle PD, Qamar A, et al. Impact of (CPG). Third universal definition of myocardial 173:94-101. doi:10.1016/j.ahj.2015.11.015 type 2 myocardial infarction (MI) on hospital-level infarction. Eur Heart J. 2012;33(20):2551-2567. 10. Berwanger O, Santucci EV, de Barros E Silva MI outcomes: implications for quality and public doi:10.1093/eurheartj/ehs184 PGM, et al; SECURE-PCI Investigators. Effect of reporting. J Am Heart Assoc. 2018;7(7):e008661. 7. Bonaca M, Scirica B, Sabatine M, et al. Loading Dose of Atorvastatin Prior to Planned doi:10.1161/JAHA.118.008661 Prospective evaluation of the prognostic Percutaneous Coronary Intervention on Major 13. Schwartz GG, Steg PG, Szarek M, et al; implications of improved assay performance with a Adverse Cardiovascular Events in Acute Coronary ODYSSEY OUTCOMES Committees http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png JAMA Cardiology American Medical Association

Toward a More Detailed Reporting of MI Reduction in Clinical Trials—A Welcome and Needed Step in the Right Direction

JAMA Cardiology , Volume 5 (7) – Jul 29, 2020

Loading next page...
 
/lp/american-medical-association/toward-a-more-detailed-reporting-of-mi-reduction-in-clinical-trials-a-cTQfOAB8Mw
Publisher
American Medical Association
Copyright
Copyright 2020 American Medical Association. All Rights Reserved.
ISSN
2380-6583
eISSN
2380-6591
DOI
10.1001/jamacardio.2020.0749
Publisher site
See Article on Publisher Site

Abstract

Effect of Evolocumab on Type and Size of Subsequent Myocardial Infarction Original Investigation Research 6. Thygesen K, Alpert JS, Jaffe AS, et al; Writing 9. Sabatine MS, Giugliano RP, Keech A, et al. syndromes: the MIRACL study: a randomized Group on the Joint ESC/ACCF/AHA/WHF Task Force Rationale and design of the Further cardiovascular controlled trial. JAMA. 2001;285(13):1711-1718. doi: for the Universal Definition of Myocardial OUtcomes Research with PCSK9 Inhibition in 10.1001/jama.285.13.1711 Infarction; ESC Committee for Practice Guidelines subjects with Elevated Risk trial. Am Heart J. 2016; 12. Arora S, Strassle PD, Qamar A, et al. Impact of (CPG). Third universal definition of myocardial 173:94-101. doi:10.1016/j.ahj.2015.11.015 type 2 myocardial infarction (MI) on hospital-level infarction. Eur Heart J. 2012;33(20):2551-2567. 10. Berwanger O, Santucci EV, de Barros E Silva MI outcomes: implications for quality and public doi:10.1093/eurheartj/ehs184 PGM, et al; SECURE-PCI Investigators. Effect of reporting. J Am Heart Assoc. 2018;7(7):e008661. 7. Bonaca M, Scirica B, Sabatine M, et al. Loading Dose of Atorvastatin Prior to Planned doi:10.1161/JAHA.118.008661 Prospective evaluation of the prognostic Percutaneous Coronary Intervention on Major 13. Schwartz GG, Steg PG, Szarek M, et al; implications of improved assay performance with a Adverse Cardiovascular Events in Acute Coronary ODYSSEY OUTCOMES Committees

Journal

JAMA CardiologyAmerican Medical Association

Published: Jul 29, 2020

References